Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly
- PMID: 23323521
- PMCID: PMC3692612
- DOI: 10.1021/jm3013882
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly
Abstract
A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generating inhibitors of protein-protein interactions demonstrated that it can be used to optimize fragment alternatives of key determinants, to combine these in an effective way, and this was achieved for compounds targeting the cyclin-dependent kinase 2 (CDK2) substrate recruitment site on the cyclin regulatory subunit. Phenylheterocyclic isosteres replacing a critical charge-charge interaction provided new structural insights for binding to the cyclin groove. In particular, these results shed light onto the key contributions of a H-bond observed in crystal structures of N-terminally capped peptides. Furthermore, the structure-activity relationship of a bis(aryl) ether C-terminal capping group mimicking dipeptide interactions was probed through ring substitutions, allowing increased complementarity with the primary hydrophobic pocket. This study further validates REPLACE as an effective strategy for converting peptidic compounds to more pharmaceutically relevant compounds.
Conflict of interest statement
Notes: The authors declare no competing financial interest.
Figures







Similar articles
-
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.J Med Chem. 2015 Jan 8;58(1):433-42. doi: 10.1021/jm5015023. Epub 2014 Dec 17. J Med Chem. 2015. PMID: 25454794 Free PMC article.
-
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.Bioorg Med Chem Lett. 2016 Aug 1;26(15):3754-60. doi: 10.1016/j.bmcl.2016.05.067. Epub 2016 Jun 10. Bioorg Med Chem Lett. 2016. PMID: 27297568 Free PMC article.
-
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.J Vis Exp. 2015 Oct 26;(105):e52441. doi: 10.3791/52441. J Vis Exp. 2015. PMID: 26554946 Free PMC article.
-
Targeting malaria with specific CDK inhibitors.Biochim Biophys Acta. 2005 Dec 30;1754(1-2):160-70. doi: 10.1016/j.bbapap.2005.07.031. Epub 2005 Sep 9. Biochim Biophys Acta. 2005. PMID: 16185941 Review.
-
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.Curr Med Chem Anticancer Agents. 2003 Jan;3(1):57-69. doi: 10.2174/1568011033353506. Curr Med Chem Anticancer Agents. 2003. PMID: 12678915 Review.
Cited by
-
Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.Molecules. 2014 Sep 11;19(9):14366-82. doi: 10.3390/molecules190914366. Molecules. 2014. PMID: 25215591 Free PMC article. Review.
-
Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.Protein Expr Purif. 2015 Sep;113:8-16. doi: 10.1016/j.pep.2015.01.013. Epub 2015 May 6. Protein Expr Purif. 2015. PMID: 25956535 Free PMC article.
-
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.J Med Chem. 2015 Jan 8;58(1):433-42. doi: 10.1021/jm5015023. Epub 2014 Dec 17. J Med Chem. 2015. PMID: 25454794 Free PMC article.
-
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.Bioorg Med Chem Lett. 2016 Aug 1;26(15):3754-60. doi: 10.1016/j.bmcl.2016.05.067. Epub 2016 Jun 10. Bioorg Med Chem Lett. 2016. PMID: 27297568 Free PMC article.
-
Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.Bioorg Med Chem. 2014 Jan 1;22(1):616-22. doi: 10.1016/j.bmc.2013.10.039. Epub 2013 Nov 7. Bioorg Med Chem. 2014. PMID: 24286762 Free PMC article.
References
-
- Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677. - PubMed
-
- Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer. 2001;1:222–231. - PubMed
-
- McInnes C, Andrews MJI, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current Medicinal Chemistry-Anti-Cancer Agents. 2003;3:57–69. - PubMed
-
- Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. Journal Of Cellular Physiology. 2002;190:160–169. - PubMed
-
- Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21WAF1 derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. Journal of Peptide Research. 2002;60:257–270. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous